{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T08:07:16Z","timestamp":1753862836724,"version":"3.41.2"},"reference-count":38,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272835"],"award-info":[{"award-number":["82272835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The purpose of this study was to evaluate the efficacy and safety of fruquintinib\u2010based therapy as a salvage therapy for patients with advanced or metastatic sarcoma, including soft tissue sarcoma (STS) and bone sarcoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with advanced or metastatic sarcoma were divided into two groups. One group received fruquintinib monotherapy, while the other received fruquintinib combined therapy. Safety and efficacy of fruquintinib\u2010based therapy were recorded and reviewed retrospectively, including progression\u2010free survival (PFS), overall response rate (ORR), and adverse events (AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between August 2021 and December 2022, 38 sarcoma patients were retrospectively included. A total of 14 patients received fruquintinib alone (including 6 STS and 8 bone sarcoma), while 24 were treated with fruquintinib combined therapy (including 2 STS and 22 bone sarcoma). The median follow\u2010up was 10.2\u2009months (95% CI, 6.4\u201311.5). For the entire population, the median PFS was 8.0\u2009months (95% CI, 5.5\u201313.0). The ORR was 13.1%, while the disease control rate (DCR) was 86.8%. The univariate analysis showed that radiotherapy history (HR, 4.56; 95% CI, 1.70\u201312.24; <jats:italic>p<\/jats:italic>\u2009=\u20090.003), bone sarcoma (HR, 0.34; 95% CI, 0.14\u20130.87; <jats:italic>p<\/jats:italic>\u2009=\u20090.024), and treatment method of fruquintinib (HR, 0.36; 95% CI, 0.15\u20130.85; <jats:italic>p<\/jats:italic>\u2009=\u20090.021) were significantly associated with PFS. The multivariate analysis showed that patients without radiotherapy history were associated with a better PFS (HR, 3.71; 95% CI: 1.31\u201310.55; <jats:italic>p<\/jats:italic>\u2009=\u20090.014) than patients with radiotherapy history. Patients in combination group reported pneumothorax (8.3%), leukopenia (33.3%), thrombocytopenia (12.5%), diarrhea (4.2%), and anemia (4.2%) as the most frequent grade 3 or higher treatment\u2010emergent AEs (TEAEs), while there was no severe TEAEs occurred in the monotherapy group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Fruquintinib\u2010based therapy displayed an optimal tumor control and an acceptable safety profile in patients with advanced or metastatic sarcoma.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.7438","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T15:34:34Z","timestamp":1720193674000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of fruquintinib\u2010based therapy in patients with advanced or metastatic sarcoma"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9751-5937","authenticated-orcid":false,"given":"Chenliang","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Oncology Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-1467","authenticated-orcid":false,"given":"Guowei","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonggang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-4396","authenticated-orcid":false,"given":"Zan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9244-6779","authenticated-orcid":false,"given":"Shuier","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0035"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0017"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-213"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1679"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.711953"},{"issue":"7","key":"e_1_2_12_7_1","first-page":"410","article-title":"Metastatic soft tissue sarcomas: a review of treatment and new pharmacotherapies","volume":"43","author":"Singhi EK","year":"2018","journal-title":"P T"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70063-4"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0606-9"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2103423"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.4420"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-020-09716-y"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051240"},{"issue":"2","key":"e_1_2_12_14_1","first-page":"39","article-title":"Vascular endothelial growth factor expression as a biomarker of prognosis in patients with chondrosarcoma, Ewing's sarcoma and osteosarcoma. Current concepts","volume":"33","author":"Capasso L","year":"2019","journal-title":"J Biol Regul Homeost Agents"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.811687"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04483"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30325-9"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.04.021"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00977-0"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30825-3"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3283622d3a"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000778"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.4161\/15384047.2014.964087"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3069-8"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0998-z"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7855"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001482"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S300430"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000463"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26265"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71136-2"},{"issue":"2","key":"e_1_2_12_34_1","first-page":"92","article-title":"Results of treatment in primary disseminated osteosarcoma. Analysis of the follow\u2010up of patients in the cooperative osteosarcoma studies COSS\u201080 and COSS\u201082","volume":"12","author":"Winkler K","year":"1989","journal-title":"Onkologie"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2009.11.026"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.141"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.08.022"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27651"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030700"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.7438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T13:33:45Z","timestamp":1721914425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.7438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":38,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/cam4.7438"],"URL":"https:\/\/doi.org\/10.1002\/cam4.7438","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e7438"}}